{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:11:06Z","timestamp":1790039466233,"version":"4.0.1"},"reference-count":195,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi-organ failure and death depending on its severity. Inadequate cardiac contractility or cardiac power secondary to acute myocardial infarction remains the most frequent cause of cardiogenic shock, although its contribution has declined over the past two decades, compared with other causes. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality. Its management is based on immediate stabilization of haemodynamic parameters so that further treatment, including mechanical circulatory support and transfer to specialized tertiary care centres, can be accomplished. With these aims, medical therapy, consisting mainly of inotropic drugs and vasopressors, still has a major role. The purpose of this article is to review current evidence on the use of these medications in patients with cardiogenic shock and discuss specific clinical settings with indications to their use.<\/jats:p>","DOI":"10.1002\/ejhf.3162","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:44:01Z","timestamp":1708670641000},"page":"411-431","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Medical Therapy of Cardiogenic Shock: Contemporary Use of Inotropes and Vasopressors"],"prefix":"10.1093","volume":"26","author":[{"given":"Mauro","family":"Riccardi","sequence":"first","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. C.C. Iliescu\u2019 , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm MASCOT, AP-HP Department of Anesthesia and Critical Care, H\u00f4pital Lariboisi\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research Inc , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Heart Centre, Department of Cardiology, Rigshospitalet-Copenhagen University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Latronico","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia , Brescia ,","place":["Italy"]},{"name":"Department of Anesthesia, Intensive Care and Emergency, ASST Spedali Civili University Hospital , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"2026010913043499400_ejhf3162-bib-0001","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0003","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0004","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0002-9343(00)00310-7","article-title":"Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: Report of the SHOCK trial registry","volume":"108","author":"Menon","year":"2000","journal-title":"Am J Med"},{"key":"2026010913043499400_ejhf3162-bib-0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4244\/EIJ-D-20-01296","article-title":"Management of cardiogenic shock","volume":"17","author":"Thiele","year":"2021","journal-title":"EuroIntervention"},{"key":"2026010913043499400_ejhf3162-bib-0006","first-page":"29","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026010913043499400_ejhf3162-bib-0007","first-page":"22","article-title":"SCAI stage reclassification at 24\u2009h predicts outcome of cardiogenic shock: Insights from the Altshock-2 registry","volume":"101","author":"Morici","year":"2023","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026010913043499400_ejhf3162-bib-0008","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005618","article-title":"Epidemiology of shock in contemporary cardiac intensive care units","volume":"12","author":"Berg","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026010913043499400_ejhf3162-bib-0009","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ejhf.1750","article-title":"Trends in cardiogenic shock complicating acute myocardial infarction","volume":"22","author":"Aissaoui","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2020.10.054","article-title":"Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time","volume":"232","author":"Jentzer","year":"2021","journal-title":"Am Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008141","article-title":"Clinical characteristics and predictors of in-hospital mortality in patients with cardiogenic shock: Results from the RESCUE registry","volume":"14","author":"Yang","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007154","article-title":"Regional variation in the management and outcomes of acute myocardial infarction with cardiogenic shock in the United States","volume":"13","author":"Vallabhajosyula","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009279","article-title":"Cardiogenic shock from heart failure versus acute myocardial infarction: Clinical characteristics, hospital course, and 1-year outcomes","volume":"15","author":"Sinha","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008736","article-title":"Quantification of vasoactive medications and the \u2018Pharmaco-mechanical continuum\u2019 in cardiogenic shock","volume":"15","author":"Vallabhajosyula","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0015","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jacc.2019.01.053","article-title":"Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock","volume":"73","author":"Vallabhajosyula","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0016","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.2021.18323","article-title":"Cardiogenic shock after acute myocardial infarction: A review","volume":"326","author":"Samsky","year":"2021","journal-title":"JAMA"},{"key":"2026010913043499400_ejhf3162-bib-0017","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJMoa1808788","article-title":"One-year outcomes after PCI strategies in cardiogenic shock","volume":"379","author":"Thiele","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913043499400_ejhf3162-bib-0018","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040931","article-title":"Patient characteristics, treatment and outcome in non-ischemic vs. ischemic cardiogenic shock","volume":"9","author":"Schrage","year":"2020","journal-title":"J Clin Med"},{"key":"2026010913043499400_ejhf3162-bib-0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","article-title":"Dobutamine for patients with severe heart failure: A systematic review and meta-analysis of randomised controlled trials","volume":"38","author":"Tacon","year":"2012","journal-title":"Intensive Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ejhf.991","article-title":"Long-term safety of intravenous cardiovascular agents in acute heart failure: Results from the European Society of Cardiology Heart Failure Long-Term Registry","volume":"20","author":"Mebazaa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2006.09.005","article-title":"Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure","volume":"153","author":"Elkayam","year":"2007","journal-title":"Am Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0022","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"2026010913043499400_ejhf3162-bib-0023","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"2026010913043499400_ejhf3162-bib-0024","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0025","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/ejhf.2320","article-title":"Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock","volume":"23","author":"Chioncel","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0026","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jacc.2019.02.051","article-title":"Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week","volume":"73","author":"Psotka","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0027","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","article-title":"Treatments targeting inotropy","volume":"40","author":"Maack","year":"2019","journal-title":"Eur Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0028","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ehf2.13859","article-title":"Advanced heart failure: Guideline-directed medical therapy, diuretics, inotropes, and palliative care","volume":"9","author":"Tomasoni","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0029","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.2814","article-title":"Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Gustafsson","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0030","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/eurheartj\/ehr026","article-title":"Cardiac inotropes: Current agents and future directions","volume":"32","author":"Hasenfuss","year":"2011","journal-title":"Eur Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0031","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","article-title":"Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan","volume":"159","author":"Papp","year":"2012","journal-title":"Int J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0032","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.jacc.2008.03.015","article-title":"Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: A randomized controlled trial in patients hospitalized with heart failure","volume":"51","author":"Gheorghiade","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0033","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","article-title":"Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan","volume":"27","author":"Haikala","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0034","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"de Backer","year":"2010","journal-title":"N Engl J Med"},{"key":"2026010913043499400_ejhf3162-bib-0035","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s00134-008-1219-0","article-title":"A comparison of epinephrine and norepinephrine in critically ill patients","volume":"34","author":"Myburgh","year":"2008","journal-title":"Intensive Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0036","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"Levy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0037","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/CCM.0b013e3181ffe0eb","article-title":"Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study","volume":"39","author":"Levy","year":"2011","journal-title":"Crit Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0038","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913043499400_ejhf3162-bib-0039","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/CCM.0b013e3181809846","article-title":"Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction","volume":"36","author":"Fuhrmann","year":"2008","journal-title":"Crit Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"2026010913043499400_ejhf3162-bib-0041","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2007.04.143","article-title":"Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty","volume":"127","author":"Samimi-Fard","year":"2008","journal-title":"Int J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0042","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/eurjhf\/hfs215","article-title":"Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: A randomized, placebo-controlled study","volume":"15","author":"Husebye","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0043","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejheart.2006.01.007","article-title":"Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0044","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/ejhf.2629","article-title":"Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock \u2013 a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC)","volume":"24","author":"Metra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0045","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/eurheartj\/ehm075","article-title":"Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: A phase II dose-ranging study","volume":"28","author":"Dzav\u00edk","year":"2007","journal-title":"Eur Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0046","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.297.15.joc70035","article-title":"Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial","volume":"297","author":"TRIUMPH Investigators","year":"2007","journal-title":"JAMA"},{"key":"2026010913043499400_ejhf3162-bib-0047","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.107.728840","article-title":"Inotropes and vasopressors: Review of physiology and clinical use in cardiovascular disease","volume":"118","author":"Overgaard","year":"2008","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0048","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2014.01.016","article-title":"Inotropes","volume":"63","author":"Francis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0049","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2013.12.276","article-title":"Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial","volume":"172","author":"Triposkiadis","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0050","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","article-title":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial","volume":"310","author":"Chen","year":"2013","journal-title":"JAMA"},{"key":"2026010913043499400_ejhf3162-bib-0051","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0140-6736(00)03495-4","article-title":"Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group","volume":"356","author":"Bellomo","year":"2000","journal-title":"Lancet"},{"key":"2026010913043499400_ejhf3162-bib-0052","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2010.07.246","article-title":"Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) trial","volume":"16","author":"Giamouzis","year":"2010","journal-title":"J Card Fail"},{"key":"2026010913043499400_ejhf3162-bib-0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108230","article-title":"Pharmacological treatment of cardiogenic shock \u2013 a state of the art review","volume":"240","author":"Bruno","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2026010913043499400_ejhf3162-bib-0054","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008402","article-title":"Dopamine versus norepinephrine in the treatment of cardiogenic shock: A PRISMA-compliant meta-analysis","volume":"96","author":"Rui","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026010913043499400_ejhf3162-bib-0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1573403X15666181212125024","article-title":"Shock \u2013 classification and pathophysiological principles of therapeutics","volume":"15","author":"Kislitsina","year":"2019","journal-title":"Curr Cardiol Rev"},{"key":"2026010913043499400_ejhf3162-bib-0056","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00134-018-5222-9","article-title":"Epinephrine and short-term survival in cardiogenic shock: An individual data meta-analysis of 2583 patients","volume":"44","author":"L\u00e9opold","year":"2018","journal-title":"Intensive Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0057","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure","volume":"28","author":"Writing Committee Members; ACC\/AHA Joint Committee Members","year":"2022","journal-title":"J Card Fail"},{"key":"2026010913043499400_ejhf3162-bib-0058","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ehf2.13893","article-title":"Norepinephrine use in cardiogenic shock patients is associated with increased 30 day mortality","volume":"9","author":"Lu","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0059","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13054-016-1387-1","article-title":"Current real-life use of vasopressors and inotropes in cardiogenic shock \u2013 adrenaline use is associated with excess organ injury and mortality","volume":"20","author":"Tarvasm\u00e4ki","year":"2016","journal-title":"Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00134-010-2073-4","article-title":"Short-term survival by treatment among patients hospitalized with acute heart failure: The global ALARM-HF registry using propensity scoring methods","volume":"37","author":"Mebazaa","year":"2011","journal-title":"Intensive Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0061","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jcp.10024","article-title":"Adrenergic regulation of cardiac myocyte apoptosis","volume":"189","author":"Singh","year":"2001","journal-title":"J Cell Physiol"},{"key":"2026010913043499400_ejhf3162-bib-0062","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4103\/0366-6999.205862","article-title":"Clinical characteristics and current interventions in shock patients in Chinese emergency departments: A multicenter prospective cohort study","volume":"130","author":"Guo","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"2026010913043499400_ejhf3162-bib-0063","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1806842","article-title":"A randomized trial of epinephrine in out-of-hospital cardiac arrest","volume":"379","author":"Perkins","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913043499400_ejhf3162-bib-0064","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/01.CIR.69.1.113","article-title":"Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine","volume":"69","author":"Liang","year":"1984","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0002-8703(99)70108-0","article-title":"Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial","volume":"138","author":"Oliva","year":"1999","journal-title":"Am Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0066","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0002-9149(90)90325-U","article-title":"Effect of dobutamine on skeletal muscle metabolism in patients with congestive heart failure","volume":"65","author":"Mancini","year":"1990","journal-title":"Am J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0067","doi-asserted-by":"crossref","first-page":"490","DOI":"10.7326\/0003-4819-99-4-490","article-title":"Drugs five years later. Dobutamine","volume":"99","author":"Leier","year":"1983","journal-title":"Ann Intern Med"},{"key":"2026010913043499400_ejhf3162-bib-0068","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0002-9149(94)90921-0","article-title":"Fever induced by dobutamine infusion","volume":"74","author":"Chapman","year":"1994","journal-title":"Am J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0069","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjcard.2003.12.069","article-title":"Dobutamine-induced eosinophilia","volume":"93","author":"El-Sayed","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0070","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-9343(80)90387-3","article-title":"Tolerance to dobutamine after a 72 hour continuous infusion","volume":"69","author":"Unverferth","year":"1980","journal-title":"Am J Med"},{"key":"2026010913043499400_ejhf3162-bib-0071","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.25011\/cim.v42i2.32813","article-title":"Efficacy of milrinone and dobutamine in low cardiac output states: Systematic review and meta-analysis","volume":"42","author":"Mathew","year":"2019","journal-title":"Clin Invest Med"},{"key":"2026010913043499400_ejhf3162-bib-0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101245","article-title":"Meta-analysis comparing the efficacy of dobutamine versus milrinone in acute decompensated heart failure and cardiogenic shock","volume":"48","author":"Biswas","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0073","first-page":"419","article-title":"Inotrope and vasopressor use in cardiogenic shock: What, when and why?","volume":"28","author":"Hu","year":"2022","journal-title":"Curr Opin Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0074","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1476-5381.2011.01588.x","article-title":"Use of inotropes and vasopressor agents in critically ill patients","volume":"165","author":"Bangash","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2026010913043499400_ejhf3162-bib-0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0002-9149(99)80420-2","article-title":"Short-term use of intravenous milrinone for heart failure","volume":"75","author":"Konstam","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0076","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCHEARTFAILURE.107.746933","article-title":"Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)","volume":"1","author":"Klein","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0077","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0735-1097(02)02134-4","article-title":"Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol","volume":"40","author":"Metra","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0078","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1074248418797357","article-title":"Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock","volume":"24","author":"Lewis","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026010913043499400_ejhf3162-bib-0079","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.clinthera.2007.08.009","article-title":"Effects of milrinone on contractility and cyclic adenosine monophosphate production induced by beta1- and beta2-adrenergic receptor activation in human myocardium","volume":"29","author":"Carceles","year":"2007","journal-title":"Clin Ther"},{"key":"2026010913043499400_ejhf3162-bib-0080","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1345\/aph.1M357","article-title":"Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure","volume":"43","author":"Jennings","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2026010913043499400_ejhf3162-bib-0081","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13054-021-03706-2","article-title":"Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: A subgroup analysis of the DOREMI trial","volume":"25","author":"Di Santo","year":"2021","journal-title":"Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0082","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/00003246-199208000-00006","article-title":"Addition of enoximone to adrenergic agents in the management of severe heart failure","volume":"20","author":"Vincent","year":"1992","journal-title":"Crit Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0083","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/0167-5273(90)90144-T","article-title":"Addition of phosphodiesterase inhibitors to adrenergic agents in acutely ill patients","volume":"28","author":"Vincent","year":"1990","journal-title":"Int J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0084","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000174667","article-title":"The role of enoximone in the treatment of cardiogenic shock","volume":"77","author":"Vincent","year":"1990","journal-title":"Cardiology"},{"key":"2026010913043499400_ejhf3162-bib-0085","first-page":"384","article-title":"Inotropes and vasopressors use in cardiogenic shock: When, which and how much?","volume":"25","author":"Levy","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0086","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000000859","article-title":"Levosimendan efficacy and safety: 20\u2009years of SIMDAX in clinical use","volume":"76","author":"Papp","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026010913043499400_ejhf3162-bib-0087","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejphar.2003.12.005","article-title":"The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig","volume":"486","author":"Szil\u00e1gyi","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"2026010913043499400_ejhf3162-bib-0088","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.fjc.0000175454.69116.9","article-title":"Two inotropes with different mechanisms of action: Contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone","volume":"46","author":"Szil\u00e1gyi","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026010913043499400_ejhf3162-bib-0089","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2125.2003.02043.x","article-title":"Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan","volume":"57","author":"Antila","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2026010913043499400_ejhf3162-bib-0090","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1002\/ehf2.13670","article-title":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: The LAICA study","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0091","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10741-021-10101-0","article-title":"Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: A systematic review and meta-analysis of 984 patients","volume":"27","author":"Elsherbini","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026010913043499400_ejhf3162-bib-0092","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: The LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0093","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: A multicentre randomized trial","volume":"16","author":"Altenberger","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0094","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ehf2.14278","article-title":"Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry","volume":"10","author":"Dobarro","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0095","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ehf2.13807","article-title":"Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients","volume":"9","author":"Milwidsky","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0096","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ejhf.3006","article-title":"Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial","volume":"25","author":"P\u00f6lzl","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0097","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0098","article-title":"Meta-analysis of placebo-controlled trials of levosimendan in acute myocardial infarction","volume":"8","author":"Tumminello","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026010913043499400_ejhf3162-bib-0099","doi-asserted-by":"crossref","first-page":"E001","DOI":"10.1532\/hsf.4267","article-title":"Effects of levosimendan preconditioning on left ventricular remodeling after myocardial reperfusion in acute myocardial infarction patients receiving percutaneous coronary intervention","volume":"25","author":"Yu","year":"2022","journal-title":"Heart Surg Forum"},{"key":"2026010913043499400_ejhf3162-bib-0100","doi-asserted-by":"crossref","DOI":"10.1007\/s00395-009-0064-9","article-title":"Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition","volume":"105","author":"H\u00f6nisch","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/17482940701358564","article-title":"Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction","volume":"10","author":"Christoph","year":"2008","journal-title":"Acute Card Care"},{"key":"2026010913043499400_ejhf3162-bib-0102","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2007.05.018","article-title":"Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty","volume":"128","author":"Dominguez-Rodriguez","year":"2008","journal-title":"Int J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0103","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/VHRM.S8856","article-title":"Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction","volume":"6","author":"Omerovic","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"2026010913043499400_ejhf3162-bib-0104","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.medin.2017.08.009","article-title":"Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis","volume":"42","author":"Fang","year":"2018","journal-title":"Med Intensiva (Engl Ed)"},{"key":"2026010913043499400_ejhf3162-bib-0105","first-page":"CD009669","article-title":"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome","volume":"11","author":"Uhlig","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010913043499400_ejhf3162-bib-0106","doi-asserted-by":"crossref","first-page":"41A","DOI":"10.1016\/j.amjcard.2006.09.005","article-title":"Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure","volume":"99","author":"Sabbah","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0107","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cardfail.2023.03.020","article-title":"Safety and efficacy of istaroxime 1.0 and 1.5 \u03bcg\/kg\/min for patients with pre-cardiogenic shock","volume":"29","author":"Metra","year":"2023","journal-title":"J Card Fail"},{"key":"2026010913043499400_ejhf3162-bib-0108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1113\/jphysiol.1994.sp020353","article-title":"Effects of angiotensin II on intracellular Ca2+ and pH in isolated beating rabbit hearts and myocytes loaded with the indicator indo-1","volume":"480","author":"Ikenouchi","year":"1994","journal-title":"J Physiol"},{"key":"2026010913043499400_ejhf3162-bib-0109","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/TCRM.S150434","article-title":"Angiotensin II: A new therapeutic option for vasodilatory shock","volume":"14","author":"Bussard","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2026010913043499400_ejhf3162-bib-0110","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0022-2828(81)90237-6","article-title":"Effects of angiotensin II on membrane current in cardiac Purkinje fibers","volume":"13","author":"Kass","year":"1981","journal-title":"J Mol Cell Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0111","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study","volume":"18","author":"Chawla","year":"2014","journal-title":"Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0112","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"2026010913043499400_ejhf3162-bib-0113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.jvca.2020.08.001","article-title":"Treatment with angiotensin II is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: A post-hoc analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study","volume":"35","author":"Klijian","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026010913043499400_ejhf3162-bib-0114","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0885066620972943","article-title":"A multicenter observational cohort study of angiotensin II in shock","volume":"37","author":"Smith","year":"2022","journal-title":"J Intensive Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajem.2023.01.050","article-title":"Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review","volume":"66","author":"Bansal","year":"2023","journal-title":"Am J Emerg Med"},{"key":"2026010913043499400_ejhf3162-bib-0116","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1053\/j.jvca.2021.07.021","article-title":"Angiotensin II: A review of current literature","volume":"36","author":"Alam","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026010913043499400_ejhf3162-bib-0117","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/CCM.0000000000002441","article-title":"Clinical experience with IV angiotensin II administration: A systematic review of safety","volume":"45","author":"Busse","year":"2017","journal-title":"Crit Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0118","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029787","article-title":"State of shock: Contemporary vasopressor and inotrope use in cardiogenic shock","volume":"12","author":"Bloom","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026010913043499400_ejhf3162-bib-0119","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00134-019-05620-2","article-title":"Vasopressin in septic shock: An individual patient data meta-analysis of randomised controlled trials","volume":"45","author":"Nagendran","year":"2019","journal-title":"Intensive Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0120","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"key":"2026010913043499400_ejhf3162-bib-0121","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.2016.10485","article-title":"Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial","volume":"316","author":"Gordon","year":"2016","journal-title":"JAMA"},{"key":"2026010913043499400_ejhf3162-bib-0122","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.amjcard.2005.07.076","article-title":"Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction","volume":"96","author":"Jolly","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0123","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ejhf.1623","article-title":"Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock","volume":"22","author":"Raju","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0124","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ejhf.1600","article-title":"Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: Results from the OptimaCC trial","volume":"22","author":"Takagi","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ejhf.1601","article-title":"Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: Dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics","volume":"22","author":"Deniau","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0126","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/01.CIR.101.12.1358","article-title":"L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock","volume":"101","author":"Cotter","year":"2000","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0127","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0195-668X(03)00193-3","article-title":"LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: A prospective randomized study","volume":"24","author":"Cotter","year":"2003","journal-title":"Eur Heart J"},{"key":"2026010913043499400_ejhf3162-bib-0128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.athoracsur.2017.02.057","article-title":"Methylene blue for vasoplegic syndrome after cardiac operation: Early administration improves survival","volume":"104","author":"Mehaffey","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"2026010913043499400_ejhf3162-bib-0129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s13181-013-0298-7","article-title":"Methylene blue for distributive shock: A potential new use of an old antidote","volume":"9","author":"Jang","year":"2013","journal-title":"J Med Toxicol"},{"key":"2026010913043499400_ejhf3162-bib-0130","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1139\/cjpp-2017-0074","article-title":"Methylene blue improves mitochondrial respiration and decreases oxidative stress in a substrate-dependent manner in diabetic rat hearts","volume":"95","author":"Duicu","year":"2017","journal-title":"Can J Physiol Pharmacol"},{"key":"2026010913043499400_ejhf3162-bib-0131","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/hmg\/ddt493","article-title":"Methylene blue rescues heart defects in a drosophila model of Friedreich's ataxia","volume":"23","author":"Tricoire","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2026010913043499400_ejhf3162-bib-0132","doi-asserted-by":"crossref","first-page":"269","DOI":"10.47803\/rjc.2021.31.2.269","article-title":"Metabolic flexibility and mitochondrial bioenergetics in the failing heart. Therapeutic approaches","volume":"31","author":"Rosca","year":"2021","journal-title":"Romanian J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0133","article-title":"Methylene blue dosing strategies in critically ill adults with shock \u2013 a retrospective cohort study","volume":"9","author":"Sari-Yavuz","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026010913043499400_ejhf3162-bib-0134","first-page":"426","article-title":"The medical treatment of cardiogenic shock: Cardiovascular drugs","volume":"27","author":"de Backer","year":"2021","journal-title":"Curr Opin Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/eurjhf\/hfn045","article-title":"Levosimendan vs. dobutamine: Outcomes for acute heart failure patients on beta-blockers in SURVIVE","volume":"11","author":"Mebazaa","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0136","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/ehf2.14510","article-title":"Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction","volume":"10","author":"Bertaina","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0137","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113384","article-title":"Hemodynamic profiles of cardiogenic shock depending on their etiology","volume":"9","author":"Gaubert","year":"2020","journal-title":"J Clin Med"},{"key":"2026010913043499400_ejhf3162-bib-0138","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-3-030-28199-1_13","volume-title":"Microcirculation","author":"Chioncel","year":"2020"},{"key":"2026010913043499400_ejhf3162-bib-0139","first-page":"706","article-title":"Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-Acute Cardiovascular Care Association Research Section","volume":"11","author":"Tavazzi","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026010913043499400_ejhf3162-bib-0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ehf2.13734","article-title":"Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: Insights from the FRENSHOCK registry","volume":"9","author":"Delmas","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272279","article-title":"Vasoactive pharmacological management according to SCAI class in patients with acute myocardial infarction and cardiogenic shock","volume":"17","author":"Udesen","year":"2022","journal-title":"PLoS One"},{"key":"2026010913043499400_ejhf3162-bib-0142","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.mehy.2013.05.002","article-title":"Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment?","volume":"81","author":"Roubille","year":"2013","journal-title":"Med Hypotheses"},{"key":"2026010913043499400_ejhf3162-bib-0143","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.hrtlng.2014.08.003","article-title":"Ivabradine during cardiogenic shock: A clinical case and review of the literature","volume":"44","author":"Bonadei","year":"2015","journal-title":"Heart Lung"},{"key":"2026010913043499400_ejhf3162-bib-0144","doi-asserted-by":"crossref","first-page":"D22","DOI":"10.1093\/eurheartjsupp\/suac024","article-title":"The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: Case reports and review of literature","volume":"24","author":"Bezati","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2026010913043499400_ejhf3162-bib-0145","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMra2207410","article-title":"Right ventricular failure","volume":"388","author":"Houston","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913043499400_ejhf3162-bib-0146","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.478","article-title":"Contemporary management of acute right ventricular failure: A statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology","volume":"18","author":"Harjola","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0147","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2020.09.005","article-title":"A standardized and comprehensive approach to the management of cardiogenic shock","volume":"8","author":"Tehrani","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0148","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/CIRCULATIONAHA.119.043080","article-title":"Value of hemodynamic monitoring in patients with cardiogenic shock undergoing mechanical circulatory support","volume":"141","author":"Saxena","year":"2020","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0149","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCULATIONAHA.116.025290","article-title":"Mechanical circulatory support devices for acute right ventricular failure","volume":"136","author":"Kapur","year":"2017","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0150","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1002\/ehf2.14093","article-title":"Prognostic value of right atrial pressure-corrected cardiac power index in cardiogenic shock","volume":"9","author":"Baldetti","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0151","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11897-022-00577-8","article-title":"Heart failure after right ventricular myocardial infarction","volume":"19","author":"N\u00e4gele","year":"2022","journal-title":"Curr Heart Fail Rep"},{"key":"2026010913043499400_ejhf3162-bib-0152","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11897-012-0104-x","article-title":"Management of acute right ventricular failure in the intensive care unit","volume":"9","author":"Green","year":"2012","journal-title":"Curr Heart Fail Rep"},{"key":"2026010913043499400_ejhf3162-bib-0153","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajem.2022.05.030","article-title":"Right heart failure: A narrative review for emergency clinicians","volume":"58","author":"Kostura","year":"2022","journal-title":"Am J Emerg Med"},{"key":"2026010913043499400_ejhf3162-bib-0154","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s10741-021-10192-9","article-title":"Right ventricular failure: A comorbidity or a clinical emergency?","volume":"27","author":"Das","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026010913043499400_ejhf3162-bib-0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00000542-198402000-00009","article-title":"Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs","volume":"60","author":"Ghignone","year":"1984","journal-title":"Anesthesiology"},{"key":"2026010913043499400_ejhf3162-bib-0156","first-page":"110","article-title":"Circulatory shock: Early diagnosis and therapy","volume":"24","author":"Valente","year":"2023","journal-title":"G Ital Cardiol (Rome)"},{"key":"2026010913043499400_ejhf3162-bib-0157","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1161\/CIR.0000000000001076","article-title":"Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock: A scientific statement from the American Heart Association","volume":"146","author":"Geller","year":"2022","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0158","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008976","article-title":"Longitudinal invasive hemodynamic assessment in patients with acute decompensated heart failure-related cardiogenic shock: A single-center experience","volume":"15","author":"Baldetti","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0159","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jchf.2023.05.022","article-title":"Accepting the pulmonary artery catheter for cardiogenic shock: Escape past equipoise?","volume":"11","author":"Siddiqi","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0160","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.amjcard.2023.06.117","article-title":"Pulmonary artery catheter use and outcomes in patients with ST-elevation myocardial infarction and cardiogenic shock treated with Impella (a nationwide analysis from the United States)","volume":"203","author":"Ismayl","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0161","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jchf.2023.04.007","article-title":"Pulmonary artery catheter use and mortality in the cardiac intensive care unit","volume":"11","author":"Kadosh","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0162","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/s13054-020-03217-6","article-title":"Association between mean arterial pressure during the first 24 hours and hospital mortality in patients with cardiogenic shock","volume":"24","author":"Burstein","year":"2020","journal-title":"Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0163","first-page":"712","article-title":"The association between mean arterial pressure and outcomes in patients with cardiogenic shock: Insights from the DOREMI trial","volume":"10","author":"Parlow","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026010913043499400_ejhf3162-bib-0164","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jacc.2020.06.043","article-title":"Optimum blood pressure in patients with shock after acute myocardial infarction and cardiac arrest","volume":"76","author":"Ameloot","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0165","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008527","article-title":"Intra-aortic balloon pumping in acute decompensated heart failure with hypoperfusion: From pathophysiology to clinical practice","volume":"14","author":"Baldetti","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0166","doi-asserted-by":"crossref","first-page":"A35","DOI":"10.1093\/eurheartj\/suab007","article-title":"Escalation and de-escalation of mechanical circulatory support in cardiogenic shock","volume":"23","author":"Bertoldi","year":"2021","journal-title":"Eur Heart J Suppl"},{"key":"2026010913043499400_ejhf3162-bib-0167","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jchf.2021.05.011","article-title":"A pragmatic approach to weaning temporary mechanical circulatory support: A state-of-the-art review","volume":"9","author":"Randhawa","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0168","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2021.32","article-title":"Pulmonary artery catheter monitoring in patients with cardiogenic shock: Time for a reappraisal?","volume":"8","author":"Bertaina","year":"2022","journal-title":"Card Fail Rev"},{"key":"2026010913043499400_ejhf3162-bib-0169","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17482940902807286","article-title":"Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance","volume":"11","author":"Tsagalou","year":"2009","journal-title":"Acute Card Care"},{"key":"2026010913043499400_ejhf3162-bib-0170","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cardfail.2023.05.001","article-title":"Pulmonary artery catheter use and risk of in-hospital death in heart failure cardiogenic shock","volume":"29","author":"Kanwar","year":"2023","journal-title":"J Card Fail"},{"key":"2026010913043499400_ejhf3162-bib-0171","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(20)31047-3","article-title":"Temporary circulatory support for cardiogenic shock","volume":"396","author":"Combes","year":"2020","journal-title":"Lancet"},{"key":"2026010913043499400_ejhf3162-bib-0172","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2022.08.807","article-title":"Randomized trials of percutaneous microaxial flow pump devices: JACC state-of-the-art review","volume":"80","author":"Pahuja","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0173","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/CIRCULATIONAHA.119.034512","article-title":"Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock: An introduction for the busy clinician","volume":"140","author":"Eckman","year":"2019","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0174","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/j.jacc.2015.10.017","article-title":"Hemodynamics of mechanical circulatory support","volume":"66","author":"Burkhoff","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0175","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006930","article-title":"Concomitant intra-aortic balloon pump use in cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation","volume":"11","author":"Vallabhajosyula","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2026010913043499400_ejhf3162-bib-0176","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.120.048792","article-title":"Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: Results from an international, multicenter cohort study","volume":"142","author":"Schrage","year":"2020","journal-title":"Circulation"},{"key":"2026010913043499400_ejhf3162-bib-0177","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacc.2018.11.038","article-title":"Venoarterial ECMO for adults: JACC scientific expert panel","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0178","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.31083\/j.rcm2204154","article-title":"Impella as unloading strategy during VA-ECMO: Systematic review and meta-analysis","volume":"22","author":"Fiorelli","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"2026010913043499400_ejhf3162-bib-0179","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13054-019-2605-4","article-title":"Epinephrine, inodilator, or no inotrope in venoarterial extracorporeal membrane oxygenation implantation: A single-center experience","volume":"23","author":"Zotzmann","year":"2019","journal-title":"Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0180","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1002\/ehf2.13370","article-title":"Epinephrine administration in venoarterial extracorporeal membrane oxygenation patients is associated with mortality: A retrospective cohort study","volume":"8","author":"Massart","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0181","doi-asserted-by":"crossref","DOI":"10.1016\/j.resuscitation.2018.07.318","article-title":"Vasopressor doses correlate with survival VA ECMO patients within the first 7\u2009days","volume":"130","author":"Wengenmeyer","year":"2018","journal-title":"Resuscitation"},{"key":"2026010913043499400_ejhf3162-bib-0182","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jacc.2018.10.085","article-title":"Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock","volume":"73","author":"Russo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913043499400_ejhf3162-bib-0183","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13613-019-0503-1","article-title":"Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit","volume":"9","author":"Vally","year":"2019","journal-title":"Ann Intensive Care"},{"key":"2026010913043499400_ejhf3162-bib-0184","article-title":"Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: A meta-analysis","volume":"8","author":"Luo","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026010913043499400_ejhf3162-bib-0185","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1053\/j.jvca.2018.04.019","article-title":"Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery \u2013 a retrospective before-and-after study","volume":"32","author":"Jacky","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026010913043499400_ejhf3162-bib-0186","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/0267659120918473","article-title":"Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno-arterial extracorporeal membrane oxygenation: Systematic review and meta-analysis","volume":"35","author":"Burgos","year":"2020","journal-title":"Perfusion"},{"key":"2026010913043499400_ejhf3162-bib-0187","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1053\/j.jvca.2021.01.019","article-title":"The effectiveness of levosimendan on veno-arterial extracorporeal membrane oxygenation management and outcome: A systematic review and meta-analysis","volume":"35","author":"Kaddoura","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026010913043499400_ejhf3162-bib-0188","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1002\/ehf2.13427","article-title":"Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial","volume":"8","author":"Ellouze","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913043499400_ejhf3162-bib-0189","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s13054-016-1533-9","article-title":"Cardiac dysfunction induced by weaning from mechanical ventilation: Incidence, risk factors, and effects of fluid removal","volume":"20","author":"Liu","year":"2016","journal-title":"Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0190","first-page":"493","article-title":"Weaning the cardiac patient from mechanical ventilation","volume":"20","author":"Dres","year":"2014","journal-title":"Curr Opin Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0191","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/rccm.201205-0939OC","article-title":"Natriuretic peptide-driven fluid management during ventilator weaning: A randomized controlled trial","volume":"186","author":"Mekontso Dessap","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0192","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jcrc.2010.01.002","article-title":"Weaning difficult-to-wean chronic obstructive pulmonary disease patients: A pilot study comparing initial hemodynamic effects of levosimendan and dobutamine","volume":"26","author":"Ouanes-Besbes","year":"2011","journal-title":"J Crit Care"},{"key":"2026010913043499400_ejhf3162-bib-0193","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1164\/rccm.202201-0175ED","article-title":"Should we wean patients off vasopressors before weaning them off ventilation?","volume":"205","author":"Monnet","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0194","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1164\/rccm.202108-2004OC","article-title":"Liberation from invasive mechanical ventilation with continued receipt of vasopressor infusions","volume":"205","author":"Zarrabian","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010913043499400_ejhf3162-bib-0195","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1164\/rccm.201712-2492LE","article-title":"Safety of extubating mechanically ventilated patients receiving vasoactive infusions: A retrospective cohort study","volume":"198","author":"Quasim","year":"2018","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/2\/411\/65514029\/eurjhf_26_2_411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/2\/411\/65514029\/eurjhf_26_2_411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:05:43Z","timestamp":1767981943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/2\/411\/8326986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":195,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,23]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3162","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"2023-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}